Article
Analysis of Naturally Occurring Resistance-Associated Variants to NS3/4A Protein Inhibitors, NS5A Protein Inhibitors, and NS5B Polymerase Inhibitors in Patients With Chronic Hepatitis C.
Gene expression - 21 Mar 2018
Sun Danhui, Dai Mingjia, Shen Shanshan, Li Chunyang, Yan Xuebing
Abstract excerpt
The first NS3/4A hepatitis C virus (HCV) protease inhibitors telaprevir and boceprevir were approved in 2011, and both NS5A and NS5B polymerase inhibitors were launched. Recently, direct-acting antivirals (DAAs) have had a major impact on patients infected with HCV. HCV DAAs are highly effective antivirals with fewer side effects. DAAs have been developed for the treatment of HCV infection in combination with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.